VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells.
Our previous studies showed that Fas expression correlates inversely with the metastatic potential of osteosarcoma (OS) cells and that the manipulation of Fas expression alters the lung metastatic phenotype. However, the role of VEGF in the growth and metastases of OS is unclear. The purpose of this study was to determine whether altering VEGF expression affects lung metastatic potential. LM7 metastatic OS cells were transfected with a small interfering RNA targeting human VEGF165 (LM7/siVEGF165) or a pcDNA4 plasmid expressing human VEGF165 (LM7/VEGF). We confirmed that VEGF165 expression was decreased in LM7/siVEGF165 cells and was increased in LM7/VEGF clones compared with control transfected clones. Fas expression was not altered in these transfected clones. We also transfected LM7 cells with Fas (LM7/Fas) or Fas together with VEGF165 (LM7/Fas/VEGF) to determine whether the overexpression of VEGF165 could enhance the metastatic potential of LM7 OS cells with high Fas expression (Fas(+)). LM7/siVEGF165 and LM7/Fas cells showed decreased lung metastatic potential. In addition, the overexpression of VEGF had no effect on the ability of LM7/Fas cells to form lung metastases. We therefore concluded that VEGF165 is critical to lung metastatic potential but is not sufficient to allow Fas(+) OS cells to survive in the Fas ligand lung microenvironment.
Jia
Shu-Fang
SF
Division of Pediatrics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Guan
Hui
H
Duan
Xiaoping
X
Kleinerman
Eugenie S
ES
D000818:Animals; D001859:Bone Neoplasms / Q000235:genetics* / Q000473:pathology*; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D005822:Genetic Vectors; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics / Q000473:pathology / Q000556:secondary; D051379:Mice; D008819:Mice, Nude; D009362:Neoplasm Metastasis / Q000235:genetics* / Q000473:pathology*; D012516:Osteosarcoma / Q000235:genetics* / Q000473:pathology*; D034741:RNA, Small Interfering / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014162:Transfection; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics*; D019014:fas Receptor / Q000235:genetics*
D034741:RNA, Small Interfering; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D019014:fas Receptor
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4503-10
17671136
Mol Cancer Res. 2007 Oct;5(10):991-9
17951400
Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8502-7
8710899
Clin Exp Metastasis. 1999;17(6):501-6
10763916
Clin Cancer Res. 2004 Dec 1;10(23):8114-9
15585647
Cancer Res. 1998 Sep 15;58(18):4185-92
9751633
Anticancer Drugs. 2002 Feb;13(2):155-61
11901308
Clin Cancer Res. 2005 Apr 1;11(7):2662-9
15814647
Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):12081-7
9342366
Oncol Rep. 2002 Jul-Aug;9(4):823-7
12066216
J Exp Med. 1998 Nov 2;188(9):1717-23
9802983
Cancer Res. 1996 Jan 1;56(1):172-81
8548760
Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3609-14
9520413
J Clin Oncol. 1987 Jan;5(1):21-6
3543236
Semin Oncol. 2002 Dec;29(6 Suppl 16):10-4
12516033
Clin Cancer Res. 2003 Aug 15;9(9):3462-8
12960138
Nat Med. 1999 Dec;5(12):1359-64
10581076
J Mol Med (Berl). 1999 Jul;77(7):527-43
10494799
J Clin Oncol. 1991 Apr;9(4):600-5
2066757
Curr Opin Biotechnol. 2000 Dec;11(6):617-24
11102799
Cancer. 2006 Mar 15;106(6):1382-8
16453328
Semin Oncol. 2003 Jun;30(3 Suppl 6):39-50
12802794
Cancer Res. 2001 May 1;61(9):3750-9
11325848
Int J Cancer. 1994 May 1;57(3):371-7
8168998
N Engl J Med. 1986 Jun 19;314(25):1600-6
3520317